Eichenauer, Dennis A., Thielen, Indra, Haverkamp, Heinz ORCID: 0000-0001-6895-4132, Franklin, Jeremy ORCID: 0000-0003-1536-0925, Behringer, Karolin, Halbsguth, Teresa, Klimm, Beate, Diehl, Volker, Sasse, Stephanie, Rothe, Achim, Fuchs, Michael, Boell, Boris, von Tresckow, Bastian, Borchmann, Peter and Engert, Andreas (2014). Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group. Blood, 123 (11). S. 1658 - 1665. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Full text not available from this repository.

Abstract

Therapy-related acute myeloid leukemia and myelodysplastic syndromes (t-AML/MDS) represent severe late effects in patients treated for Hodgkin lymphoma (HL). Because more recent data are scarce, we retrospectively analyzed incidence, outcome, and risk factors for the development of t-AML/MDS after HL. A total of 11 952 patients treated for newly diagnosed HL within German Hodgkin Study Group trials between 1993 and 2009 were considered. At a median follow-up of 72 months, t-AML/MDS was diagnosed in 106/11 952 patients (0.9%). Median time from HL treatment to t-AML/MDS was 31 months. The median age of patients with t-AML/MDS was higher than in the whole patient group (43 vs 34 years, P < .0001). Patients who received 4 or more cycles of BEACOPP(escalated) had an increased risk to develop t-AML/MDS when compared with patients treated with less than 4 cycles of BEACOPPescalated or no BEACOPP chemotherapy (1.7% vs 0.7% vs 0.3%, P < .0001). The median overall survival (OS) for all t-AML/MDS patients was 7.2 months. However, t-AML/MDS patients proceeding to allogeneic stem cell transplantation had a significantly better outcome with a median OS not reached after a median follow-up of 41 months (P < .001).

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Eichenauer, Dennis A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Thielen, IndraUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Haverkamp, HeinzUNSPECIFIEDorcid.org/0000-0001-6895-4132UNSPECIFIED
Franklin, JeremyUNSPECIFIEDorcid.org/0000-0003-1536-0925UNSPECIFIED
Behringer, KarolinUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Halbsguth, TeresaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Klimm, BeateUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Diehl, VolkerUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Sasse, StephanieUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Rothe, AchimUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Fuchs, MichaelUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Boell, BorisUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
von Tresckow, BastianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Borchmann, PeterUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Engert, AndreasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-443390
DOI: 10.1182/blood-2013-07-512657
Journal or Publication Title: Blood
Volume: 123
Number: 11
Page Range: S. 1658 - 1665
Date: 2014
Publisher: AMER SOC HEMATOLOGY
Place of Publication: WASHINGTON
ISSN: 1528-0020
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
INVOLVED-FIELD RADIOTHERAPY; SECONDARY LEUKEMIA; FINAL ANALYSIS; CHEMOTHERAPY; BEACOPP; DISEASE; TRIAL; RISK; ABVD; TRANSPLANTATIONMultiple languages
HematologyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/44339

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item